Correlia Biosystems Company
Rapid Diagnostics and Proteomics. Correlia Biosystems, Inc. is a spinout from UC Berkeley developing protein measurement tools that are cost-efficient, rapid, and customizable. Their versatile SimpleScan technology has applications ranging from point-of-care diagnostics to rapid and multiplexed proteomics research.
Correlia Biosystems develops streamlined assay platforms to reduce the time and cost for quantifying proteins for proteomic and pharmaceutical applications. Our research instruments provide multiplexing capabilities for large protein panels including cytokines and post-translational modifications with unparalleled speed and automation. We are dedicated to reducing the cost and time to market for candidate drug compounds, and facilitating the access of researchers to large panel protein studies.
Correlia Biosystems develops streamlined assay platforms to reduce the time and cost for quantifying proteins for proteomic and pharmaceutical applications. Our research instruments provide multiplexing capabilities for large protein panels including cytokines and post-translational modifications with unparalleled speed and automation. We are dedicated to reducing the cost and time to market for candidate drug compounds, and facilitating the access of researchers to large panel protein studies.
Technology:
MarketPlace
Industry:
P4 Medicine
Headquarters:
United States
Founded Date:
2013
Employees Number:
1-10
Funding Status:
Seed
Investors Number:
3
Total Funding:
$995K
Estimated Revenue:
$1M to $10M
Last Funding Type:
Seed
Register and Claim Ownership